创新药产业

Search documents
A股第一!2400亿巨头涨停
天天基金网· 2025-05-23 12:20
以下文章来源于东方财富网 ,作者辣笔小强 东方财富网 . 东方财富网,中国财经门户,提供7*24小时财经资讯及全球金融市场报价,汇聚全方位的综合财经新闻 和金融市场资讯。 上天天基金APP搜索【777】开户即可领98元券包 ,优选基金10元起投!限量发放!先到先得! 周五A股三大指数呈冲高回落态势,收盘集体下跌,创业板指以1.18%领跌。沪深两市成交额为1.16万 亿元,较上一交易日放量529亿元。盘面上,可控核聚变、贵金属、创新药、维生素等板块涨幅居前, 港口、游戏、算力、电力等板块跌幅居前。 | A股 全球 | 港股 美股 ETF | | 期货 分类 | | --- | --- | --- | --- | | 沪深京 | 板块 创业板 | | 科创板 北交所 | | 行业板块 | | | | | 贵金属 | | 化学制药 | 医疗服务 | | 1.96% | | 1.67% | 1.17% | | 西部黄金 4.76% | | 海森药业 10.01% | 阳光诺和 12.55% | | 矢药商业 | | 化纤行业 | 汽车整车 | | 0.61% | | 0.60% | 0.55% | | 一心堂 10. ...
逾2500家企业披露2024年年报 港股公司整体业绩增长 新经济龙头表现亮眼
Shang Hai Zheng Quan Bao· 2025-05-06 18:39
Core Insights - The overall performance of Hong Kong stocks is improving, with net profits exceeding HKD 5 trillion, a year-on-year increase of approximately 10% [1] - Over 110 companies reported a net profit growth exceeding 100%, primarily from new economy sectors such as internet technology, biomedicine, and renewable energy [2][3] - Key sectors showing significant profit improvement include information technology, finance, and healthcare, with a notable recovery in consumer sector performance [1][4] Company Performance - Companies like Tongdao Liepin achieved a staggering net profit growth of 176.9 times, driven by AI product innovation despite challenges in the recruitment market [2] - JD Logistics reported a net profit of RMB 6.198 billion, a year-on-year increase of 905.78%, attributed to digital management and automation [2] - WuXi AppTec's net profit grew by 277.2%, benefiting from rapid expansion in the biopharmaceutical sector [2] - Yang Ming Marine Transport Corporation's net profit reached USD 366 million, a 1666.93% increase, driven by green shipping demand and route expansion [3] - Geely Automobile's net profit surged by 213% to RMB 16.632 billion, with electric vehicle sales reaching 888,000 units, a 92% increase [3] Sector Analysis - The information technology sector is experiencing a strong recovery, with companies like Kuaishou and TCL Electronics reporting net profit increases of 139.76% and 136.59%, respectively [4] - The biopharmaceutical sector is also seeing robust growth, with companies like China Resources Medical and Dongrui Pharmaceutical reporting net profit increases of 119.6% and 73.3% [5] - New consumption companies are benefiting from a recovery in consumer demand, with Pop Mart and Mixue Group reporting net profit increases of 188.77% and 41.41%, respectively [5] Future Outlook - Analysts predict that Hong Kong's overall profitability will remain high in 2025, supported by structural advantages and a concentration of leading companies in the market [6]
“3000亿巨头”或5月港股上市:恒瑞医药加速资本突围与产业升级
2 1 Shi Ji Jing Ji Bao Dao· 2025-05-06 01:08
21世纪经济报道记者季媛媛上海报道 "3000亿巨头"恒瑞医药成功闯关港交所聆讯,有望在5月迎来其在香港市场的亮相。 5月5日,港交所官网发布恒瑞医药的PHIP版招股书,市场将此视为其顺利通过港交所聆讯的强烈暗 示。若一切按计划推进,这家国内创新药领军企业将最迟在5月登陆港股,标志着其继药明康德、百济 神州后,成为又一家在"A+H"两大平台布局的医药巨头。 对于此次港交所上市的深远战略,恒瑞医药早前已明确表态:首先,H股上市将有效扩大其国际知名 度,香港资本市场的国际投资者基础广泛,有助于提升公司在全球医药行业的品牌影响力;其次,本次 上市可进一步优化资本结构并开拓新的融资渠道,为公司多元化融资提供助力;再者,本次上市有助于 公司拓展海外业务和国际研发合作,增强国际布局,进一步实现海外市场的突破。 一位券商医药行业分析师在接受21世纪经济报道记者采访时表示,在行业变革加剧、资本环境多变的大 背景下,恒瑞医药的港股上市不仅是企业战略的重要一步,也映射出我国创新药产业在多方面压力下的 突破之路。 "恒瑞医药的香港上市,不只是单一企业的资本动作,更是我国创新药产业从政策扶持走向国际竞争的 写照。在港股流动性紧缩和A ...